« Back
Home /
Amiloride

Amiloride

Item no.	HY-B0285-10mM
Manufacturer	MedChem Express
CASRN	2609-46-3
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 1 ea
Category	Oncology Cardiovascular Research Ischemia & Reperfusion Injury Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Ji, H.L., et al. delta ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol, 2012. 303(12): p. L1013-26.\|[2]Teiwes J, et al. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007 Jan;20(1):109-17.\|[3]Giamarchi A, et al. A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J. 2010 Apr 7;29(7):1176-91. ACS Nano. 2023 Apr 14.\|Adv Funct Mater. 2024 Oct 31.\|Adv Sci (Weinh). 2023 Dec 14:e2307880.\|Am J Transl Res. 2021 Jul 15;13(7):7538-7555.\|Cell Commun Signal. 2023 May 4;21(1):99.\|Cell Metab. 2022 Dec 6;34(12):2018-2035.e8.\|Cell Mol Biol Lett. 2024 Dec 3;29(1):149.\|Cell Physiol Biochem. 2018;51(6):2564-2574. \|Commun Biol. 2022 Nov 14;5(1):1248.\|Environ Sci Technol. 2021 Feb 11.\|FASEB J. 2025 Jan 15;39(1):e70298.\|Int J Biol Macromol. 2024 Aug 5;277(Pt 3):134517.\|J Am Chem Soc. 2018 Dec 12;140(49):17234-17240.\|J Control Release. 2024 Oct 26:S0168-3659(24)00725-9.\|J Leukoc Biol. 2024 Jul 16:qiae159.\|J Nanobiotechnology. 2020 Jan 31;18(1):26.\|J Pharm Anal. 2025 Jan 3.\|J Pharmaceut Biomed. 2020, 113870.\|Microb Pathog. 2019 Jul 18:103638. \|Mol Pharm. 2025 Mar 3.\|Nanotechnology. 2018 Feb 23;29(8):085101.\|Nat Biomed Eng. 2024 Sep 13.\|Nat Nanotechnol. 2024 Aug 26.\|Small Methods. 2020 Dec 18.\|Theranostics. 2019 May 31;9(13):3732-3753.\|Acta Pharm Sin B. 2024 Jul 27.\|Biomaterials. 2022 May;284:121529.\|Biosens Bioelectron. 2025 Jan 25:274:117184.\|Br J Pharmacol. 2020 Aug;177(15):3473-3488. \|Cell Mol Immunol. 2024 Jun 13.\|Cell Rep. 2022 May 31;39(9):110880.\|Food Chem. 2024 Sep 8;463(Pt 1):141196.\|Int J Biol Macromol. 14 March 2022.\|iScience. 19 October 2022, 105403.\|J Ethnopharmacol. 2022 Mar 5;115171.\|J Neuroinflammation. 2022 Feb 22;19(1):53.\|mBio. 2025 Feb 18:e0378724.\|Sci Total Environ. 2021, 146523.\|Theranostics. 2020 May 17;10(15):6581-6598. \|Transl Res. 2023 Sep 5;S1931-5244(23)00143-3.
Smiles	O=C(C1=NC(Cl)=C(N)N=C1N)NC(N)=N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MK-870
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	Apoptosis; Sodium Channel; TRP Channel
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	229.631
Product Description	Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC[1]) and urokinase-type plasminogen activator receptor (uTPA[2]). Amiloride is a blocker of polycystin-2 (PC2; TRPP2[3]) channel.
Manufacturer - Research Area	Metabolic Disease; Cardiovascular Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Membrane Transporter/Ion Channel; Neuronal Signaling
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-B0285-10mM-safety-datasheet.pdf